Research Article
Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
Table 1
Baseline characteristics.
| | | Whole cohort | Matched cohort | | WBI | Mastectomy alone | value | WBI + RNI | PMRT | value | WBI | Mastectomy alone | value | WBI + RNI | PMRT | value | | N = 429 | N = 1630 | N = 91 | N = 220 | N = 419 | N = 419 | N = 87 | N = 87 |
| | Age (years) | | Median (range) | 52 (27–78) | 57 (23–92) | | 50 (31–78) | 53.5 (31–78) | | 52 (27–78) | 52 (28–92) | | 50 (31–78) | 52 (31–78) | | | <50 | 178 (41.5%) | 477 (29.3%) | <0.05 | 44 (48.4%) | 80 (36.4%) | <0.05 | 170 (40.6%) | 177 (42.2%) | >0.05 | 40 (46.0%) | 34 (39.1%) | >0.05 | | ≥50 | 251 (58.5%) | 1153 (70.7%) | | 47 (51.6%) | 140 (63.6%) | | 249 (59.4%) | 242 (57.8%) | | 47 (54.0%) | 53 (60.9%) | |
| | Pathological stage | | | <0.05 | | | <0.05 | | | >0.05 | | | >0.05 | | T1N0 | 326 (76.0%) | 876 (53.7%) | | 0 (0.0%) | 0 (0.0%) | | 316 (75.4%) | 312 (74.5%) | | 0 (0.0%) | 0 (0.0%) | | | T1N1 | 18 (4.2%) | 114 (7.0%) | | 64 (70.3%) | 98 (44.5%) | | 18 (4.3%) | 14 (3.3%) | | 60 (69.0%) | 57 (65.5%) | | | T2N0 | 76 (17.7%) | 520 (31.9%) | | 2 (2.2%) | 7 (3.2%) | | 76 (18.1%) | 79 (18.9%) | | 2 (2.3%) | 4 (4.6%) | | | T2N1 | 9 (2.1%) | 120 (7.4%) | | 25 (27.5%) | 115 (52.3%) | | 9 (2.1%) | 14 (3.3%) | | 25 (28.7%) | 26 (29.9%) | |
| | Grade | | | <0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | I | 36 (8.4%) | 85 (5.2%) | | 4 (4.4%) | 4 (1.8%) | | 34 (8.1%) | 34 (8.1%) | | 3 (3.4%) | 2 (2.3%) | | | II | 178 (41.5%) | 753 (46.2%) | | 38 (41.8%) | 99 (45.0%) | | 173 (41.3%) | 165 (39.4%) | | 38 (43.7%) | 30 (34.5%) | | | III | 155 (36.1%) | 539 (33.1%) | | 34 (37.4%) | 86 (39.1%) | | 153 (36.5%) | 159 (37.9%) | | 34 (39.1%) | 38 (43.7%) | | | Unknown | 60 (14.0%) | 253 (15.5%) | | 15 (16.5%) | 31 (14.1%) | | 59 (14.1%) | 61 (14.6%) | | 12 (13.8%) | 17 (19.5%) | |
| | Histological subtype | | | >0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | Ductal | 379 (88.3%) | 1408 (86.4%) | | 83 (91.2%) | 203 (92.3%) | | 369 (88.1%) | 365 (87.1%) | | 81 (93.1%) | 80 (92.0%) | | | Lobular | 14 (3.3%) | 54 (3.3%) | | 1 (1.1%) | 7 (3.2%) | | 14 (3.3%) | 12 (2.9%) | | 1 (1.1%) | 0 (0.0%) | | | Other | 36 (8.4%) | 168 (10.3%) | | 7 (7.7%) | 10 (4.5%) | | 36 (8.6%) | 42 (10.0%) | | 5 (5.7%) | 7 (8.0%) | |
| | Molecular subtype | | | <0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | Luminal A-like | 163 (38.0%) | 593 (36.4%) | | 28 (30.8%) | 50 (22.7%) | | 161 (38.4%) | 158 (37.7%) | | 26 (29.9%) | 22 (25.3%) | | | Luminal B-like (HER2 negative) | 110 (25.6%) | 406 (24.9%) | | 26 (28.6%) | 59 (26.8%) | | 109 (26%) | 121 (28.9%) | | 26 (29.9%) | 25 (28.7%) | | | Luminal B-like (HER2 positive) | 29 (6.8%) | 180 (11.0%) | | 6 (6.6%) | 26 (11.8%) | | 29 (6.9%) | 30 (7.2%) | | 6 (6.9%) | 4 (4.6%) | | | HER2 positive (nonluminal) | 25 (5.8%) | 191 (11.7%) | | 9 (9.9%) | 34 (15.5%) | | 25 (6.0%) | 19 (4.5%) | | 9 (10.3%) | 13 (14.9%) | | | TNBC | 84 (19.6%) | 231 (14.2%) | | 18 (19.8%) | 37 (16.8%) | | 84 (20.0%) | 77 (18.4%) | | 16 (18.4%) | 18 (20.7%) | | | Unknown | 18 (4.2%) | 29 (1.8%) | | 4 (4.4%) | 14 (6.4%) | | 11 (2.6%) | 14 (3.3%) | | 4 (4.6%) | 5 (5.7%) | |
| | Adjuvant chemotherapy | | | >0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | No | 165 (38.5%) | 644 (39.5%) | | 3 (3.3%) | 6 (2.7%) | | 159 (37.9%) | 171 (40.8%) | | 3 (4.3%) | 3 (3.4%) | | | Yes | 264 (61.5%) | 969 (59.4%) | | 86 (94.5%) | 208 (94.5%) | | 260 (62.1%) | 247 (58.9%) | | 82 (94.3%) | 81 (93.1%) | | | Unknown | 0 (0.0%) | 17 (1.0%) | | 2 (2.2%) | 6 (2.7%) | | 0 (0.0%) | 1 (0.2%) | | 2 (2.3%) | 3 (3.4%) | |
| | Targeted therapy in HER2 positive tumor | | | >0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | No | 22 (40.7%) | 129 (34.5%) | | 3 (20.0%) | 20 (33.3%) | | 22 (40.7%) | 22 (44.0%) | | 3 (20.0%) | 2 (11.8%) | | | Yes | 31 (57.4%) | 234 (62.6%) | | 12 (80.0%) | 39 (65.0%) | | 31 (57.4%) | 26 (52.0%) | | 12 (80.0%) | 14 (82.4%) | | | Unknown | 1 (1.9%) | 11 (2.9%) | | 0 (0.0%) | 1 (1.7%) | | 1 (1.9%) | 2 (4.0%) | | 0 (0.0%) | 1 (5.9%) | |
| | Endocrine therapy in HR-positive tumor | | | <0.05 | | | >0.05 | | | >0.05 | | | >0.05 | | No | 5 (1.6%) | 110 (9.1%) | | 1 (1.6%) | 2 (1.4%) | | 5 (1.6%) | 9 (2.8%) | | 1 (1.7%) | 0 (0.0%) | | | Yes | 308 (96.9%) | 1089 (90.4%) | | 60 (96.8%) | 131 (88.5%) | | 301 (97.7%) | 312 (97.2%) | | 58 (96.7%) | 51 (92.7%) | | | Unknown | 5 (1.6%) | 5 (0.4%) | | 1 (1.6%) | 15 (10.1%) | | 2 (0.6%) | 0 (0.0%) | | 1 (1.7%) | 4 (7.3%) | |
|
|
WBI, whole breast irradiation; RNI, regional nodal irradiation; PMRT, postmastectomy radiotherapy; TNBC, triple-negative breast cancer; HR, hormone receptor.
|
